Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Tighter EU rules could...

    Tighter EU rules could trigger antibiotic shortage; says Fresenius

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-06-09T09:00:21+05:30  |  Updated On 13 Aug 2021 4:42 PM IST

    Fresenius said that under the draft proposals, the bulk-freeze-dryers that is used to produce the antibiotic would have to be sterilised more frequently, providing no additional safety benefits but slashing output capacity by 40-45%.


    FRANKFURT: German drugmaker Fresenius warned that stricter production norms being considered by Europe's drug regulator could compound shortages of a life-saving antibiotic that is used by about 25 million patients globally each year.


    The market for piperacillin-tazobactam is highly concentrated with Fresenius and Chinese rival Qilu supplying almost the entire European market between them. Production outages at Qilu have already caused repeated stock shortages over the past three years.


    The European Medicines Agency is working on a revision of good manufacturing practices (GMP) that govern the production of sterile drugs such as infusions and injections to take into account the latest technology developments.


    Fresenius said that under the draft proposals, the bulk-freeze-dryers that is used to produce the antibiotic would have to be sterilised more frequently, providing no additional safety benefits but slashing output capacity by 40-45%.


    "We have formally lodged our concerns, and we have suggested solutions. But in our dialogue with EMA and other bodies involved we haven't had the impression that our message came across, yet," said Marc-Alexander Mahl, in charge of generic drugs and complex formulations at the Kabi division of Fresenius.


    Though EMA was "a great regulatory body" and the GMP review an important initiative overall, piperacillin shortages should be avoided because second-choice drugs would put patients' lives at risk from avoidable infections, he argued.


    Piperacillin, given in combination with efficiency-booster tazobactam, is a broad-spectrum antibiotic used to combat serious infections such as sepsis or pneumonia.


    The company cited a study as showing that lack of piperacillin could result in more than 2,000 additional deaths per year from serious infections in Europe as doctors resort to less effective alternatives.


    The non-profit Access to Medicine Foundation (AMF) warned in a report last year of an emerging crisis in the global anti-infectives market, with piperacillin particularly exposed, as fragile drug supply chains were relying on just a few big suppliers.


    LONG PROCESS


    Fresenius said that upgrading its production lines would take about five years, longer than a transition period of six months to two years typically granted after the regulatory change.


    A spokeswoman for EMA said the regulator had consulted widely with the industry.


    "It may be that the next version of the document will have some changes in the text from the version that was published for consultation," she added.


    The EMA's working group of GMP inspectors will discuss the review and industry concerns this week, with the publication of the final version not expected before early next year, she said.


    "It is important to have high standards and companies around the world need to keep investing in their plants," the Access to Medicine Foundation's Executive Director Jayasree Iyer told Reuters.


    "But the risks are clear especially in a market where a lot of manufacturers are disincentivised to stay on board and there's more and more dependency on fewer manufacturers."


    Rule changes in Europe could have considerable knock-on effects in developing countries and exacerbate drug shortages there, she added.


    When piperacillin is lacking, physicians typically give antibiotics with a narrower spectrum, running the risk of sparing some harmful bacteria and possibly triggering resistant germs.


    Most antibiotics are cheap, off-patent generic medicines, offering low-profit margins compared to modern patent-protected drugs for diseases like cancer - offering manufacturers little incentive to invest in new production facilities.


    Also Read: Investors keep food firms on warning over antibiotics
    Access to Medicine FoundationAMFantibioticantibiotic shortageantibioticsbroad spectrum antibioticEMAEuropeEuropean Medicines AgencyFreseniusGerman drugmaker FreseniusGMPgood manufacturing practicespiperacillinpiperacillin tazobactamPneumoniatazobactam
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok